A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Deferiprone (Primary)
- Indications Kidney disorders
- Focus Pharmacodynamics
- Sponsors CorMedix
- 30 Mar 2014 New trial record